Pfizer introduced on Monday that it’s halting growth of its oral weight-loss tablet after one affected person skilled liver points.
The corporate mentioned it halted growth of danuglipron, an oral drug being investigated for power weight administration, after discovering {that a} “participant in one of the dose-optimization studies experienced potential drug-induced liver injury,” which was resolved after the affected person stopped utilizing the drug.
Among the many over 1,400 individuals who took the drug, the variety of instances with raised liver enzymes was about the identical as what’s seen with different accepted medicine in the identical class.
WEIGHTWATCHERS CEO SIMA SISTANI OUT IN ABRUPT EXIT, EMBRACED WEIGHT LOSS DRUGS
“While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients,” Chris Boshoff, chief scientific officer for Analysis and Improvement at Pfizer, mentioned in a press release.
The corporate mentioned the information from danuglipron’s second medical growth program might be offered at a scientific discussion board or submitted for publication in a peer-reviewed journal sooner or later, though it did not specify when.
Pfizer mentioned it halted growth of danuglipron after discovering {that a} “participant in one of the dose-optimization studies experienced potential drug-induced liver injury.” (REUTERS/Carlo Allegri / Reuters)
The corporate’s determination marks a serious setback for the pharmaceutical large because it competes with rivals Eli Lilly and Novo Nordisk within the profitable weight-loss drug market. Morgan Stanley Analysis re-evaluated the worldwide marketplace for weight problems medicine, and is now anticipating it to achieve between $105 billion and $144 billion in 2030. That is up from an earlier projection of $77 billion. In 2023, gross sales of branded weight problems medicine notched $6 billion, in keeping with Morgan Stanley Analysis.
DOCTORS DRAW ATTENTION TO SAFETY ISSUES ASSOCIATED WITH POPULAR WEIGHT-LOSS DRUGS
Competitors within the area is intensifying, with Novo Nordisk and Eli Lilly vying for dominance by decreasing the price of their blockbuster weight-loss medicine for cash-paying sufferers – successfully increasing entry for these with out insurance coverage via their very own self-pay pharmacy packages.
Pfizer competes with rivals Eli Lilly and Novo Nordisk within the profitable weight-loss drug market. (Scanpix Denmark/Liselotte Sabroe by way of Reuters / Reuters Pictures)
This is not the primary setback for Pfizer’s danuglipron, both. The corporate scrapped growth of its twice-daily weight-loss tablet in 2023 after a medical trial confirmed “high rates” of antagonistic unintended effects amongst customers.
On the time, the corporate mentioned “most common adverse events were mild and gastrointestinal in nature consistent with the mechanism” however, many individuals skilled nausea, as much as 73%, vomiting, as much as 47%, and diarrhea, as much as 25%.
Ticker Safety Final Change Change % PFE PFIZER INC. 21.91 +0.32
+1.48%
LLY ELI LILLY & CO. 732.41 +11.50
+1.60%
NVO NOVO NORDISK A/S 64.73 +3.52
+5.75%
GET FOX BUSINESS ON THE GO BY CLICKING HERE
“High discontinuation rates, greater than 50%, were seen across all doses compared to approximately 40% with placebo,” it added.
FOX Enterprise’ Greg Norman contributed to this report.
